2023 World Conference on Lung Cancer (Posters)-P2.05. Genomic Variants Associated with Response to Immune Checkpoint Inhibitors Amongst Asian Patients with Advanced NSCLC

P2.05. Genomic Variants Associated with Response to Immune Checkpoint Inhibitors Amongst Asian Patients with Advanced NSCLC - PDF(Slides)

Back to course

Pdf Summary

Researchers conducted a pioneering pharmacogenomics genome-wide association study (GWAS) to identify genomic variants that predict the response to immune checkpoint inhibitors (ICIs) in Asian patients with advanced non-small cell lung cancer (NSCLC). They compared responders, defined as patients with complete or partial response or sustained stable disease for 24 weeks, to non-responders, defined as patients with progressive disease or stable disease for 24 weeks.<br /><br />The study found seven novel variants in four genes that were associated with ICI response in advanced NSCLC. These genes include IGFBP7-AS1, BMP6, LINC02751, and LDLRAD4. Ongoing efforts are being made to validate these findings in an independent patient cohort.<br /><br />The research involved collecting patient samples and isolating their DNA for genotyping. Patient clinical data was also collected. The study included a total of 100 patients, with 76 responders and 24 non-responders to ICI treatment. The analysis revealed significant associations between the identified variants and response to ICIs.<br /><br />The study also reported the progression-free survival (PFS) and overall survival (OS) of the patients. The median PFS for responders was 16 months, compared to 2.7 months for non-responders. The median OS for responders was 53.4 months, while non-responders had a median OS of 6.5 months.<br /><br />The findings from this study provide important insights into the genomic basis for varying responses to ICIs in Asian patients with advanced NSCLC. Identifying these predictive genomic signatures could help guide treatment decisions and improve patient outcomes by enabling personalized medicine approaches. Further validation of these findings in larger patient cohorts will be crucial to confirm their clinical applicability.

Asset Subtitle

Yiqing Huang

Meta Tag

Speaker Yiqing Huang

Topic Metastatic NSCLC: Immunotherapy - Biomarker

Keywords

pharmacogenomics

genome-wide association study

genomic variants

immune checkpoint inhibitors

Asian patients

non-small cell lung cancer

responders

non-responders

novel variants

genes